Ono Pharmaceutical Co Ltd
TSE:4528
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 714
2 812.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ono Pharmaceutical Co Ltd
Net Margin
Ono Pharmaceutical Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | JP |
| Market Cap | 805.1B JPY |
| Net Margin |
20%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Net Margin |
-79%
|
| Country | US |
| Market Cap | 744.2B USD |
| Net Margin |
20%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Net Margin |
-4%
|
| Country | DK |
| Market Cap | 3.3T DKK |
| Net Margin |
35%
|
| Country | US |
| Market Cap | 373.9B USD |
| Net Margin |
17%
|
| Country | US |
| Market Cap | 258.4B USD |
| Net Margin |
19%
|
| Country | CH |
| Market Cap | 200.6B CHF |
| Net Margin |
20%
|
| Country | UK |
| Market Cap | 161.8B GBP |
| Net Margin |
13%
|
| Country | CH |
| Market Cap | 180.7B CHF |
| Net Margin |
35%
|
| Country | US |
| Market Cap | 146B USD |
| Net Margin |
7%
|
Ono Pharmaceutical Co Ltd
Glance View
Ono Pharmaceutical Co., Ltd., a leader in the Japanese biopharmaceutical landscape, has carved out a reputation for innovation and dedication to addressing unmet medical needs. Founded in 1717, this company has evolved over the centuries and transformed from a traditional medicine supplier into a cutting-edge player in the global pharmaceutical arena. Ono’s commitment to research and development is highlighted by its focus on oncology, immunology, and neurology, boasting a robust pipeline that includes groundbreaking therapies, such as the highly regarded monoclonal antibody, Opdivo (nivolumab). Opdivo has not only become a cornerstone in cancer treatment but also solidified Ono’s position as the go-to partner for health institutions looking to leverage advanced therapeutics for patient care. For investors, Ono Pharmaceutical represents a compelling opportunity within the biopharmaceutical sector, given its strong intellectual property portfolio and solid financial performance. The company has cultivated strategic collaborations with prominent global players, expanding its reach beyond Japan and accessing international markets. With revenue driven by both its proprietary drugs and partnerships, Ono demonstrates resilience amid fluctuating industry conditions. Moreover, the firm's ongoing investments in innovative development programs signal a forward-thinking approach, likely to yield new products that can drive future growth. As global healthcare increasingly leans towards personalized medicine and novel treatments, Ono Pharmaceutical stands poised to capitalize on these trends, making it a noteworthy consideration for investors seeking long-term value and impact in the healthcare space.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Ono Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of 19.6%.
You don't have any saved screeners yet
